PharmaCyte Biotech Inc (PMCB)

[1234jklm]

The technology works

The 2014 canine tests show this. As do the first Lohr trials.

It’s such a leading edge technology because it uses live cells and so approval requirements are many times higher and have been increased by the fda in recent years. Very few live cell therapies are fda approved and only in the last year.

It’s a tiny company that contracts out for its services.

But it has an affordable way to shrink tumors without side effects and shrinking tumors can make them operable and smaller operations for smaller tumors gave better results.

I believe this could become standard pre operation practice for cancerous tumors...a massive and growing market.

Then there’s all the other possible applications. Including a treatment for diabetes1

Since the great test results from Eurofins fr our master cell bank this is not going to 3s and 4s like it did in no news periods before.

Biotech requires great patience.